IconOVir Bio

IconOVir Bio

  • Founded: 2020
  • Location: San Diego, CA
  • Employee range: 11 - 50
  • Clinical stage: Clin1
  • Therapy area: advanced solid tumors
  • Drug types: ONC
  • Lead product: ICVB-1042
  • Product link: https://iconovir.com/
  • Funding: $77M A Jan 2021



job board

Short description:

Oncolytic Virus Therapy

Drug notes:

Contact us to add description: recruit@workinbiotech.com

Long description:

Iconovir Bio is a preclinical-stage biotechnology company developing next-generation oncolytic virus therapies to improve the treatment of cancer. Oncolytic viruses are viruses that are engineered to kill cancer cells while leaving healthy cells unharmed. Iconovir Bio's oncolytic viruses are designed to be more potent, selective, and persistent than previous generations of oncolytic viruses. The company's viruses are also designed to be less immunogenic, which means that they are less likely to trigger an immune response from the patient. Iconovir's proprietary platform has the potential to develop new and more effective treatments for cancer.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com